The Impact of Diabetes Medications on Fertility and Conception

The Impact of Diabetes Medications on Fertility and Conception

For the millions of Americans of reproductive age managing diabetes, optimizing blood glucose is intricately linked to fertility outcomes. The medications used to achieve glycemic targets have direct and indirect effects on ovulation, sperm quality, conception rates, and fetal development. Navigating preconception planning requires a thorough understanding of how each diabetes therapy influences the reproductive system. More than 37 million Americans live with diabetes, and a significant portion are of childbearing age. The relationship between blood glucose control and fertility is well established: poorly managed diabetes can disrupt ovulation in women, reduce sperm quality in men, and increase the risk of pregnancy complications. Diabetes medications are the primary tool for achieving glycemic targets, but each drug class carries distinct implications for those trying to conceive. Understanding these differences empowers patients to work with their healthcare team to optimize treatment before and during pregnancy.

The Link Between Diabetes and Reproductive Health

How Diabetes Affects Female Fertility

Elevated blood glucose levels interfere with the hypothalamic-pituitary-ovarian (HPO) axis, the hormonal cascade that regulates ovulation. Women with uncontrolled type 1 or type 2 diabetes often experience anovulatory cycles, irregular menstruation, and diminished ovarian reserve. Insulin resistance, a hallmark of type 2 diabetes and polycystic ovary syndrome (PCOS), further compounds these issues by promoting hyperandrogenism, elevated androgen levels that suppress normal follicle development. Even subtle elevations in HbA1c above 6.5% have been associated with longer time to pregnancy. Chronic hyperglycemia also induces oxidative stress in the ovarian follicles, impairing oocyte quality and reducing fertilization potential. Inflammatory cytokines, elevated in poorly controlled diabetes, further disrupt endometrial receptivity, making implantation more challenging.

How Diabetes Affects Male Fertility

Diabetes also impairs male reproductive function through multiple mechanisms. Oxidative stress from hyperglycemia causes DNA fragmentation in sperm, while vascular and neuropathic changes secondary to diabetes can lead to erectile dysfunction and retrograde ejaculation. Hyperglycemia damages the seminiferous tubules and reduces sperm motility, concentration, and normal morphology. Men with diabetes are more likely to require assisted reproductive technologies such as intracytoplasmic sperm injection (ICSI) compared to men without the condition. Improved glycemic control with appropriate medications can partially reverse these effects, particularly by reducing oxidative stress and improving hormonal profiles. It is essential that both partners achieve optimal glucose control when planning a pregnancy.

Types of Diabetes Medications and Their Effects on Fertility

Choosing the right medication regimen is critical for optimizing fertility. The table below provides a quick reference, while the detailed sections discuss each drug class in depth.

Medication Class	Recommended Preconception Action	Discontinuation Window
SGLT2 Inhibitors	Discontinue	At least 3 months before conception
GLP-1 Agonists	Discontinue	At least 2 months before conception
Thiazolidinediones	Discontinue	At least 1 month before conception
Sulfonylureas	Switch to insulin or metformin	At least 1 month before conception
Metformin	Continue (with consideration)	N/A, generally continued
Insulin	Continue, optimize dosing	N/A, essential therapy

Insulin

Role in Preconception and Pregnancy

Insulin remains the cornerstone of therapy for type 1 diabetes and is frequently used in type 2 diabetes when oral agents are insufficient or during pregnancy. Achieving tight glucose control with insulin improves ovulation rates and reduces the risk of miscarriage and congenital anomalies. For women with type 1 diabetes, continuous subcutaneous insulin infusion (insulin pumps) combined with continuous glucose monitoring provides the precise dosing needed to support a healthy pregnancy while minimizing hypoglycemia. Modern insulin analogs offer improved pharmacokinetic profiles that allow for more flexible dosing and better postprandial control.

Safety and Efficacy Profile

Insulin does not cross the placenta in significant amounts and is considered safe for use during conception and throughout pregnancy. It has no known direct adverse effects on male fertility; when combined with good glycemic management, it can improve sperm parameters by reducing oxidative stress. For these reasons, the American Diabetes Association recommends insulin as the preferred agent for managing diabetes in pregnancy. While newer insulins such as faster-acting aspart and lispro have been studied in pregnancy, traditional regular insulin and NPH remain safe and effective options.

Metformin

Direct Effects on Ovarian Function

Metformin is the first-line oral medication for type 2 diabetes and is also widely prescribed for PCOS due to its insulin-sensitizing properties. Metformin improves ovulation by reducing insulin levels and lowering androgen production in the ovaries. Multiple randomized controlled trials show that women with PCOS who take metformin have higher ovulation rates and improved live birth rates compared to placebo. The medication is generally continued through the first trimester to reduce the risk of early pregnancy loss, particularly in women with PCOS or pre-existing type 2 diabetes.

PCOS and Ovulation Induction

Metformin has a favorable safety profile; it is classified as FDA Pregnancy Category B and is not associated with major malformations. In fact, metformin use during pregnancy has been associated with reduced rates of preeclampsia and large-for-gestational-age infants in some studies. In men, metformin may improve erectile function and sperm quality indirectly through better glycemic control and reduced systemic inflammation. Routine screening for vitamin B12 deficiency is recommended for those on long-term metformin therapy, as deficiency can itself impact fertility.

Sulfonylureas

Mechanism and Limitations

Sulfonylureas such as glipizide and glyburide stimulate the pancreas to release more insulin. While effective for lowering blood glucose, their role in preconception is limited. Glyburide crosses the placenta and has been associated with neonatal hypoglycemia and macrosomia. Data on sulfonylureas and fertility are sparse; they do not directly improve ovulation or sperm function. Many clinicians switch women from sulfonylureas to insulin or metformin before attempting conception. For men, sulfonylureas carry a small risk of hypoglycemia but no documented direct effects on fertility. Given the availability of safer alternatives, sulfonylureas are not recommended in the preconception period.

SGLT2 Inhibitors

Emerging Considerations and Risks

SGLT2 inhibitors like empagliflozin and dapagliflozin lower blood glucose by increasing urinary glucose excretion. They offer significant cardiovascular and renal benefits for patients with type 2 diabetes, which makes them appealing for long-term use. However, they raise concerns for pregnancy. Animal studies show renal toxicity in developing fetuses, and human data are insufficient to guarantee safety. For this reason, SGLT2 inhibitors are typically discontinued at least three months before planned conception. There is no evidence that SGLT2 inhibitors directly impair ovulation or spermatogenesis, but their forced discontinuation can destabilize glycemic control, which indirectly harms fertility.

Off-Label Use and Research

Emerging research suggests these drugs may have positive effects on ovarian function in PCOS models by reducing hyperandrogenism and improving metabolic profiles. However, clinical guidance remains conservative, and these agents should not be used for ovulation induction outside of clinical trials. Patients should discuss bridging therapy with insulin or metformin when discontinuing an SGLT2 inhibitor for preconception.

GLP-1 Receptor Agonists

Weight Loss and Ovulation Effects

GLP-1 agonists such as semaglutide and liraglutide enhance insulin secretion, slow gastric emptying, and promote significant weight loss. Weight reduction itself improves fertility outcomes in women with obesity and PCOS. Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, offers even greater weight reduction and is being studied for its effects on ovulation and metabolic health. These medications can be highly effective for restoring ovulation in anovulatory women with obesity.

Preconception Discontinuation Protocol

However, these medications carry a theoretical risk of delayed gastric emptying that could affect nutritional status during early pregnancy, and animal studies have shown fetal abnormalities at high doses. Current recommendations advise discontinuing GLP-1 agonists at least two months before attempting pregnancy. The longer half-life of some formulations, such as semaglutide, may require an even longer washout period. In men, GLP-1 agonists may improve sperm quality through weight loss and reduced systemic inflammation.

Thiazolidinediones

Thiazolidinediones (pioglitazone, rosiglitazone) improve insulin sensitivity but are less commonly used today due to cardiovascular and bone density concerns. Pioglitazone can induce ovulation in women with PCOS by reducing insulin resistance, similar to metformin. However, these drugs cross the placenta and have been associated with fetal growth restriction in animal models. Most guidelines recommend discontinuing thiazolidinediones before conception. Their impact on male fertility is not well studied, but no significant adverse effects have been documented.

DPP-4 Inhibitors

DPP-4 inhibitors (e.g., sitagliptin, linagliptin) are commonly prescribed for type 2 diabetes but have limited data supporting their use in the preconception period. Animal studies have not shown major teratogenic risk, but human data is insufficient to recommend continuation. Most clinicians will switch patients from a DPP-4 inhibitor to insulin or metformin prior to conception. These agents do not appear to directly impact ovarian or testicular function, but the conservative approach is to discontinue them in favor of more established therapies.

PCOS and Metformin: A Special Case

Polycystic ovary syndrome affects up to 12% of women of childbearing age and is the most common cause of anovulatory infertility. Metformin is one of the few medications that directly addresses the underlying insulin resistance driving PCOS-related infertility. The drug lowers serum insulin, which in turn reduces ovarian androgen production. This restores follicular development and normal ovulation in many women. A landmark study published in the New England Journal of Medicine found that metformin combined with clomiphene citrate improved ovulation and pregnancy rates compared to clomiphene alone. For women with PCOS who do not ovulate with metformin alone, adding letrozole or gonadotropins may be necessary.

Metformin is also recommended during ovulation induction with assisted reproductive technologies to improve oocyte quality and reduce the risk of ovarian hyperstimulation syndrome (OHSS). The American Association of Clinical Endocrinologists (AACE) guidelines emphasize that metformin should be considered first-line therapy for the management of PCOS-related infertility, especially in women with insulin resistance or impaired glucose tolerance.

Preconception Care and Medication Adjustment

Planning Ahead and Glycemic Targets

Optimal fertility outcomes begin months before conception. The American Diabetes Association recommends that women with diabetes achieve an HbA1c below 6.5% before attempting pregnancy, as elevated glucose levels during the first four to six weeks of gestation, often before a woman knows she is pregnant, can cause neural tube defects and cardiac malformations. For individuals with frequent hypoglycemia, a target of <7% may be more appropriate. This requires careful medication planning and often a transition to insulin therapy.

Medication Switches and Discontinuation Timelines

The following table summarizes the recommended actions for common diabetes medications when planning conception. These timelines should be reviewed with an endocrinologist to ensure stable glycemic control during the transition.

Medication Class	Recommended Preconception Action	Discontinuation Window
SGLT2 Inhibitors	Discontinue	At least 3 months before conception
GLP-1 Agonists	Discontinue	At least 2 months before conception
Thiazolidinediones	Discontinue	At least 1 month before conception
Sulfonylureas	Switch to insulin or metformin	At least 1 month before conception
Metformin	Continue (with consideration)	N/A, generally continued
Insulin	Continue, optimize dosing	N/A, essential therapy

Multivitamin and Supplement Support

Alongside medication adjustments, all women planning pregnancy should take a daily supplement containing at least 400 mcg of folic acid. Women with diabetes have a two- to fourfold increased risk of neural tube defects, so a higher dose of 5 mg folic acid is often prescribed. Additional supplementation with vitamin B12 may be warranted for those taking metformin, as chronic use can deplete B12 stores, and deficiency is linked to infertility and early pregnancy loss. Vitamin D levels should also be assessed and optimized, as deficiency is common in women with PCOS and has been associated with insulin resistance and reduced fertility.

Safety During Early Pregnancy

Once pregnancy is confirmed, the priority shifts to maintaining glycemic targets while protecting the developing fetus. Insulin remains the gold standard for diabetes management during pregnancy because it does not cross the placenta and allows precise dose titration. Metformin is often continued, especially in women with PCOS or type 2 diabetes, as evidence supports its safety and benefit in reducing pregnancy complications such as preeclampsia and large-for-gestational-age infants. Medications that are contraindicated in early pregnancy include SGLT2 inhibitors, GLP-1 agonists, and thiazolidinediones. Sulfonylureas are avoided in the first trimester due to transplacental passage and risk of neonatal hypoglycemia.

It is crucial to monitor for hypoglycemia, which can be more frequent during early pregnancy due to nausea, vomiting, and changes in insulin sensitivity. Women should have a plan for managing hypoglycemia and access to rapid-acting glucose sources.

Assisted Reproductive Technology Considerations

Diabetes medications influence outcomes in in vitro fertilization (IVF) and other assisted reproductive technologies. Metformin improves oocyte maturity, embryo quality, and clinical pregnancy rates in women with PCOS undergoing IVF. It also reduces the risk of ovarian hyperstimulation syndrome, a serious complication of gonadotropin stimulation. For women with type 1 diabetes undergoing IVF, an insulin pump with continuous glucose monitoring provides the most stable control during ovarian stimulation, when estrogen levels rise and insulin sensitivity fluctuates. Men with diabetes undergoing IVF or ICSI should ensure optimal glycemic control, as sperm DNA fragmentation, exacerbated by hyperglycemia, can reduce fertilization and implantation rates. Intracytoplasmic sperm injection is often recommended to bypass defects in sperm binding and motility associated with diabetes.

Working With Your Healthcare Team

Coordinating care among an endocrinologist, a reproductive endocrinologist, and a maternal-fetal medicine specialist is essential for patients with diabetes planning pregnancy. A preconception visit should include medication review, HbA1c measurement, assessment of diabetes complications (retinopathy, nephropathy, neuropathy), and screening for thyroid dysfunction. Shared decision-making regarding medication selection and timing of conception leads to better adherence and outcomes. Patients should feel empowered to ask about glycemic targets, the safety of each medication during pregnancy, and the signs of hypoglycemia, which can be more frequent during early pregnancy due to nausea and vomiting. Psychological support is also beneficial, as managing diabetes around conception and pregnancy can be a significant source of stress and diabetes distress.

Conclusion

Diabetes medications exert a profound influence on fertility and conception outcomes. Insulin and metformin are the safest and most studied options, with demonstrated benefits for ovulation, sperm quality, and pregnancy health. Newer classes such as SGLT2 inhibitors and GLP-1 agonists must be discontinued well before conception due to insufficient safety data, which requires careful timing and bridging therapy. Individualized preconception planning, including medication adjustments, folic acid supplementation, and tight glycemic control, is the foundation for a successful pregnancy in individuals with diabetes. By partnering with their healthcare team and understanding how each medication affects reproductive function, patients can navigate the journey to parenthood with confidence and clarity.